These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 18409505)
1. [Gout and hyperuricemia: Introduction]. Hosoya T Nihon Rinsho; 2008 Apr; 66(4):621-3. PubMed ID: 18409505 [No Abstract] [Full Text] [Related]
2. Homozygous frameshift mutation in the SLC22A12 gene in a patient with primary gout and high levels of serum uric acid. Vázquez-Mellado J; Alvarado-Romano V; Burgos-Vargas R; Jiménez-Vaca AL; Pozo-Molina G; Cuevas-Covarrubias SA J Clin Pathol; 2007 Aug; 60(8):947-8. PubMed ID: 17660342 [No Abstract] [Full Text] [Related]
3. [Historical review of gout and hyperuricemia investigations]. Nakamura T Nihon Rinsho; 2008 Apr; 66(4):624-35. PubMed ID: 18409506 [TBL] [Abstract][Full Text] [Related]
4. [Genetic testing and gene-based testing for hyperuricemia and gout]. Taniguchi A; Kamatani N Nihon Rinsho; 2005 Dec; 63 Suppl 12():285-9. PubMed ID: 16416809 [No Abstract] [Full Text] [Related]
5. Control of renal uric acid excretion and gout. Taniguchi A; Kamatani N Curr Opin Rheumatol; 2008 Mar; 20(2):192-7. PubMed ID: 18349750 [TBL] [Abstract][Full Text] [Related]
6. [Treatment of hyperuricemia and gout based on the guideline for the management of hyperuricemia and gout]. Taniguchi A Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):330-4. PubMed ID: 21139283 [No Abstract] [Full Text] [Related]
7. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia]. Fujimori S Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523 [TBL] [Abstract][Full Text] [Related]
8. Absence of SLC22A12/URAT1 gene mutations in patients with primary gout. Torres RJ; De Miguel E; Bailen R; Puig JG J Rheumatol; 2012 Sep; 39(9):1901. PubMed ID: 22942308 [No Abstract] [Full Text] [Related]
9. [Introduction of the new guideline for the management of hyperuricemia and gout with special reference to its policy]. Nakajima H; Matsuzawa Y Nihon Rinsho; 2003 Jan; 61 Suppl 1():442-9. PubMed ID: 12629763 [No Abstract] [Full Text] [Related]
10. [Gout - from pathogenesis to treatment - progress in the XXI century]. Cal-Kocikowska J; Nawrocka M; Bogdański P Pol Merkur Lekarski; 2015 Jun; 38(228):354-9. PubMed ID: 26098658 [TBL] [Abstract][Full Text] [Related]
12. Update on the management of hyperuricemia and gout. Pillinger MH; Keenan RT Bull NYU Hosp Jt Dis; 2008; 66(3):231-9. PubMed ID: 18937638 [TBL] [Abstract][Full Text] [Related]
13. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N; Kumar S; Stamp L; Gow P J Rheumatol; 2006 Aug; 33(8):1646-50. PubMed ID: 16783857 [TBL] [Abstract][Full Text] [Related]
14. High-resolution melting analysis for the rapid detection of an intronic single nucleotide polymorphism in SLC22A12 in male patients with primary gout in China. Guan M; Zhang J; Chen Y; Liu W; Kong N; Zou H Scand J Rheumatol; 2009; 38(4):276-81. PubMed ID: 19306160 [TBL] [Abstract][Full Text] [Related]
15. A common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of gout. Taniguchi A; Urano W; Yamanaka M; Yamanaka H; Hosoyamada M; Endou H; Kamatani N Arthritis Rheum; 2005 Aug; 52(8):2576-7. PubMed ID: 16059895 [No Abstract] [Full Text] [Related]
16. [Treatment of hyperuricemia and gout]. Gröbner W; Walter-Sack I Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988 [No Abstract] [Full Text] [Related]